Outlining the clinical evidence landscape for FXI(a) inhibition: - stroke and bleeding prevention for patients with AF at risk of stroke - secondary stroke prevention in acute non-cardioembolic ischemic stroke or high-risk TIA
Topic:
Stroke in Atrial Fibrillation
Sponsored by Bayer
Event:
ESC Congress 2023
Congress Presentation
About the speakers
Professor Joris R De Groot
Amsterdam University Medical Centre, Amsterdam (Netherlands (The))
16
presentations
3
followers
Professor Mukul Sharma
Population Health Research Institute, Hamilton (Canada)
4
presentations
0
follower
5 more presentations in this session
Epidemiology of stroke and disease burden
Speaker: Professor C. Blomstrom-Lundqvist (Orebro, SE)
Uncovering the unmet need for patients:
- with atrial fibrillation at risk of stroke
- acute non-cardioembolic ischemic stroke or high-risk TIA
Speaker: Professor C. Blomstrom-Lundqvist (Orebro, SE) Professor M. Sharma (Hamilton, CA)
Evolution of FXI(a) as a target for antithrombotic therapy
Speaker: Doctor J. Weitz (Hamilton, CA)
Access the full session
About the event
